Imaging Correlates of Renal Cell Carcinoma Biological Features

Renal Cell Carcinoma Clinical Trial

Official title:

LCCC 1213: Defining Molecular and Functional Imaging Correlates of Renal Cell Carcinoma Biological Features

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01665703
• Other study ID #: LCCC1213
• Status: Completed
• Phase: N/A
• Start date: August 2012
• Est. completion date: January 2019

Study information

• Verified date: January 2021
• Source: UNC Lineberger Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This pilot study is designed to evaluate imaging parameters indicative of underlying tumor biology. Patients with large renal masses (>3 cm, or at the discretion of the investigator) who are planning to undergo nephrectomy will be identified, and recruited to undergo a contrast-enhanced magnetic resonance-Fluorodeoxyglucose-positron emission tomography (MR-FDG-PET) scan.

Description:

This pilot study is designed to evaluate imaging parameters indicative of underlying tumor biology. Patients with large renal masses (>3 cm, or at the discretion of the investigator) who are planning to undergo nephrectomy will be identified, and recruited to undergo a contrast-enhanced magnetic resonance-Fluorodeoxyglucose-positron emission tomography (MR-FDG-PET) scan. Samples collected from their tumor after it is removed will undergo a variety of laboratory tests, including biomarker assessments and genotyping. By examining primary renal masses via a combination of MR and FDG-PET functional imaging in concert with tissue based tests, areas of hypermetabolism and hypervascularization will be evaluated as features of HIF activation or tumor subtype.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: January 2019
• Est. primary completion date: November 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• = 18 years of age (no upper age limit)

• Informed consent obtained and signed

• Clinically suspected RCC based on imaging performed prior to enrollment

• Planned nephrectomy schedule that can accommodate a MR-FDG-PET scan within 4 weeks prior to surgery

• Willing to undergo gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake by the tumor within 4 weeks prior to nephrectomy

• Willing to consent for genetic and proteomic analysis of tumor and germline nucleic acids

• Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to FDG-PET-MRI

• Breast feeding women cannot do so for 24 hours after FDG injection

• Patient is willing to fast for 4 hours, including avoiding any sugar-containing drinks.

• Patient is willing to drink at least 32 ounces of water (or other no-sugar-containing fluids) within 4 hours prior to arriving for scans.

Exclusion Criteria:

• History of severe reaction to gadolinium-enhanced MRI

• Poorly controlled diabetes mellitus

• Inability to tolerate PET and/or MRI

• Presence of pacemaker or intracranial aneurysm clip

• GFR < 30mL/min as measured via Cockcroft-Gault equation

• Inability to lie flat for >1 hour

• Pregnant female

• History of a prior malignancy within past 5 years are excluded unless they have been disease free for 3 or more years or unless they have a completely resected non-melanoma skin cancer, low risk prostate cancer, or other low risk tumor history at the discretion of the investigator.

• Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Renal Cell Carcinoma

Intervention

Procedure:
• FDG PET/MR
Patients will be asked to undergo a voluntary gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake within 4 weeks prior to surgery.

Locations

Country	Name	City	State
United States	Lineberger Comprehensive Cancer Center	Chapel Hill	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
UNC Lineberger Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of FDG-PET-MRI making useful measurements that might be then used to globally assess tumor biological features	This is a feasibility study. Feasibility will be determined by the quality of the FDG-PET-MRI measurements. That is, the measurements represent what the investigators hope they are measuring. With 10 of 10, the 100% rate has an exact 95% confidence interval of 69% to 100%. The interval width, representing a measure of precision, is 31%. The tumor biological features that will be assessed include genetic analyses performed for commonly mutated genes in kidney cancer (VHL, PBRM1, SETD2, HIF1, UTX, MLL2) and protein expression analyses performed on HIF1 and HIF2 protein expression using standard immunohistochemistry. These genetic and protein expression analyses will be performed on tissue samples collected within four weeks of imaging from tissue removed via nephrectomy.	4 weeks

External Links

•   Lineberger Comprehensive Cancer Center website
•   National Cancer Institute (NCI) website